WO2005105834A1 - Procedimiento para la producción en levaduras de cápsidas virales vacías compuestas por proteínas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv) - Google Patents
Procedimiento para la producción en levaduras de cápsidas virales vacías compuestas por proteínas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv) Download PDFInfo
- Publication number
- WO2005105834A1 WO2005105834A1 PCT/ES2005/070052 ES2005070052W WO2005105834A1 WO 2005105834 A1 WO2005105834 A1 WO 2005105834A1 ES 2005070052 W ES2005070052 W ES 2005070052W WO 2005105834 A1 WO2005105834 A1 WO 2005105834A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pnp2
- protein
- ibdn
- amino acid
- acid sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 169
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 160
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 37
- 241000700605 Viruses Species 0.000 title claims abstract description 25
- 210000000234 capsid Anatomy 0.000 title claims abstract description 25
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 25
- 230000002458 infectious effect Effects 0.000 title claims abstract description 21
- 208000027312 Bursal disease Diseases 0.000 title claims abstract description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims description 57
- 238000000034 method Methods 0.000 title claims description 27
- 230000003612 virological effect Effects 0.000 title claims description 8
- 229960005486 vaccine Drugs 0.000 claims abstract description 35
- 239000013598 vector Substances 0.000 claims abstract description 30
- 241000702626 Infectious bursal disease virus Species 0.000 claims abstract description 18
- 238000001415 gene therapy Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- 230000014509 gene expression Effects 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 27
- 235000013330 chicken meat Nutrition 0.000 claims description 12
- 241000287828 Gallus gallus Species 0.000 claims description 11
- 241000271566 Aves Species 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 101150003852 pnp2 gene Proteins 0.000 claims description 7
- 241000286209 Phasianidae Species 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 241000272517 Anseriformes Species 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 241000235058 Komagataella pastoris Species 0.000 claims description 3
- 241000235648 Pichia Species 0.000 claims description 3
- 241000235070 Saccharomyces Species 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 241000271567 Struthioniformes Species 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 43
- 238000003058 natural language processing Methods 0.000 description 32
- 239000002245 particle Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 102100021960 Leukemia NUP98 fusion partner 1 Human genes 0.000 description 9
- 108010076039 Polyproteins Proteins 0.000 description 9
- 241000238631 Hexapoda Species 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 206010006811 Bursitis Diseases 0.000 description 5
- 108090000565 Capsid Proteins Proteins 0.000 description 5
- 102100023321 Ceruloplasmin Human genes 0.000 description 5
- 238000011537 Coomassie blue staining Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000001338 self-assembly Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108700010756 Viral Polyproteins Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004627 transmission electron microscopy Methods 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101710184528 Scaffolding protein Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000007261 sc medium Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10023—Virus like particles [VLP]
Definitions
- the invention relates to a process for the production of empty viral capsids composed of proteins derived from the pNP2 protein (pNP2 *) of the virus causing infectious bursitis disease (IBDN).
- Said capsids can be used in the production of vaccines and in the elaboration of vectors for gene therapy.
- the virus causing infectious bursitis disease is a member of the Birnaviridae family that infects different avian species and is directly responsible for a serious immunosuppressive disease causing significant economic losses in the global poultry industry ( Sharma JM et al. 2000. Infectious bursal disease virus of chickens: pathogenesis and immunosuppression. Developmental and Comparative Immunology 24: 223-235; van den Berg TP et al. 2000. Infectious bursal disease (Gumboro disease). Revue strig et technique ( International Office of Epizootics) 19: 509-543).
- NP4 polypeptide 4 (28 kDa)
- NP4 polypeptide 4
- the NP2, NP3, and NP4 proteins are produced from the proteolytic processing of a precursor polypeptide (or polyprotein) of a size of 109 kDa. This precursor is autocatalytically processed by releasing peptides pNP2 (NPX), NP3 and
- the NP4 domain which is located in the central region of the polyprotein, belongs to the Ion family of proteases and is responsible for proteolytic cutting.
- the pNP2 and NP3 polypeptides are directly responsible for the assembly of the capsids.
- NP2 mature form of the protein
- NP3 the mature form of the protein
- viruses have developed strategies that allow the sequential and correct interaction between each of its components.
- the conventional vaccines used for the control of infectious bursitis are based on the use of strains, with different degrees of virulence, of the IBDN itself grown in cell culture or in embryonated eggs. Extracts containing infectious material are subjected to chemical inactivation processes to produce inactivated vaccines or are used directly to produce live attenuated vaccines.
- the latter type of vaccines has the classic drawbacks associated with the use of live attenuated vaccines, namely, the risk of mutations that reverse the virulence of the virus or make it lose its immunogenicity.
- NLPs are an alternative to the use of live attenuated vaccines and recombinant sub-unit vaccines.
- the NLPs are obtained by self-assembly of all or part of the constituent sub-units of the viral capsid and mimic the structure and antigenic properties of the native virion although they lack genetic material and are therefore unable to replicate.
- NLPs can be used as vectors of molecules of biological interest, for example, nucleic acids, peptides, proteins, etc.
- the use of different vectors for the expression of IBDN genes has allowed the development of different viral assembly production systems. In this sense, the production of different IBDN NLPs by viral polyprotein expression has been described using different expression systems, for example, mammalian cells (Fernández-Arias A et al. 1998. Expression of ORF Al of infectious bursal disease virus results in the formation of virus-like particles. J. Gen. Nirol. 79: 1047-54) or alternative vectors based on the use of recombinant baculovirus (rBNs) (Nakharia No. 1997.
- NP3 the scaffolding protein of infectious bursal disease virus
- NLPs produced by the expression of a chimeric form of the viral polyprotein formed by the fusion of it to a heterologous protein in order to improve the efficiency in the formation of NLPs
- IBDN NLPs The various methods of production of IBDN NLPs described previously suffer from different defects that reduce or prevent their applicability for the generation of vaccines against IBDN since: (i) vectors developed to produce IBDN NLPs are based on the use of viruses recombinants, derived from the vaccine virus or baculovirus, so that the production of said NLPs is made from mammalian or insect cells; however, these production systems are very expensive for their application in the industrial production of veterinary vaccines; (ii) the production of IBDN NLPs in mammalian cells is based on the use of vaccine virus recombinants; However, in addition to the fact that this production system has a very high cost, the use of a recombinant virus capable of infecting both mammals and birds does not meet the biosecurity conditions necessary for its use as a vaccine; (iii) the production of IBDN NLPs in insect cells using conventional expression systems, for example, rBNs that express only viral polyprotein, in addition to being
- Naccine 21: 4736-4743 who, although they describe the expression of the gene encoding the NP2 protein of IBDN in Pichia pastoras and the use of a partially purified material containing said IBDN rNP2 protein to immunize animals do not describe the formation of capsids formed by self-assembly of said rNP2 expressed in P. pastoris.
- NLPs-pNP2 * IBDN NLPs provided by this invention
- This strategy is based on the use of a gene expression system or vector that allows the expression of an IBDN pNP2 * in yeasts and the formation of IBDN NLPs-pNP2 *, with a very high yield and a very low economic cost .
- Vaccines obtained using said NLPs-pNP2 * have numerous advantages since, on the one hand, the manipulation of highly infectious material is avoided, the potential risk of new IBDN mimics is prevented and the use of live virus in the virus is eliminated. poultry farms, thus preventing the risk of dissemination of vaccine strains of IBDN to the Environment, and, on the other hand, allows the development of differential diagnostic systems to discriminate between vaccinated and infected animals.
- the present invention relates to a process for the production of said IBDN NLPs-pNP2 * based on the gene expression of an IBDN pNP2 * protein in yeasts.
- IBDN NLPs-pNP2 * which exhibit antigenic or immunogenic activity against infection caused by IBDN, constitute a further aspect of this invention.
- the use of said IBDN NLPs-pNP2 * in the preparation of medicaments, such as vaccines and vectors for gene therapy, and / or for diagnostic purposes constitutes an additional aspect of this invention.
- Such vaccines and vectors constitute additional aspects of the present invention.
- FIGURES shows a schematic representation of the plasmid pESCURAinv / pNP2-456.
- the plasmid contains an AD ⁇ fragment that contains the region corresponding to the IBDN polyprotein that encodes from residue 1 to residue 456 of the NPDN protein of IBDN, under the transcriptional control of the galactose-inducible promoter called GALl.
- GALl galactose-inducible promoter
- Figure 3A shows the microscopic characterization of NLPs-pNP2 * purified; fractions 21 to 26 of the gradient shown in Figure 2 were mixed and analyzed by transmission electron microscopy (TEM); In the image shown, the presence of numerous isometric particles with a size of approximately 23 nm is observed. The sample was stained with uranyl acetate.
- Figure 3B shows the result of a biochemical analysis, specifically, the sample (NLP) was analyzed by SDS-PAGE followed by coomassie blue staining. The molecular weight marker (M) used was Dual Color (BIO-RAD).
- Figure 3C shows the result of an antigenic analysis, specifically, the sample (NLP) was analyzed by Western blotting using IBDN anti-NP2 serum.
- M indicates the lane corresponding to the molecular weight markers (Dual Color, BIO-RAD).
- Figure 4 is a bar chart illustrating the characterization of the humoral response against NLPs-pNP2-456. Said NLPs-pNP2-456 were used to immunize 1-day SPF chickens (Example 2). Immunization was performed using a group of 7 chickens, with a single dose of antigen intramuscularly. As a control, a group of chickens that were injected intramuscularly with an identical volume of the antigen diluent (PBS) was used. Samples were taken at intervals of 7 days until day 35. Serum samples were analyzed by ELISA using a serum sample dilution of 1/500.
- PBS antigen diluent
- IBDN refers to the different strains of IBDN belonging to any of the known serotypes (1 or 2) [for illustrative purposes see review by van den Berg TP, Eterradossi To, Toquin D, Meulemans G., in Rev Sci Tech 2000 19: 509-43].
- pNP2 * protein refers, in general, to a protein whose amino acid sequence is constituted by the amino acid sequence comprised between the remainder 1 and the "n" moiety of the IBDN pNP2 protein, where "n” It is an integer between 441 and 501 and includes any of the different forms of pNP2 proteins representative of any of the aforementioned IBDN strains [ ⁇ CBI protein databank], according to the definition made by Sánchez and Rodr ⁇ guez (1999) ( Sánchez AB, Rodr ⁇ guez JF. Proteolytic processing in infectious bursal disease virus: identification of the polyprotein cleavage sites by site-directed mutagenesis. Nirology.
- proteins substantially homologous to said proteins IBDN pNP2 ie proteins whose amino acid sequences have a degree of identity, with respect to said IBDN pNP2 proteins, of at least 60%, preferably at least 80%, more preferably of at least 90% and, even more preferably of at least 95%.
- Particular pNP2 * proteins are named following the "pNP2-n" format, where "n" is the one defined previously.
- said pNP2 * protein is a protein selected from the group consisting of: (i) the pNP2-441 protein, whose amino acid sequence is constituted by the amino acid sequence comprised between residue 1 and residue 441 of the protein IBDN pNP2; (ii) the pNP2-452 protein, whose amino acid sequence is constituted by the amino acid sequence comprised between the remainder 1 and the remainder 452 of the IBDN pNP2 protein; (iii) the pNP2-456 protein, whose amino acid sequence is constituted by the amino acid sequence comprised between the remainder 1 and the remainder 456 of the IBDN pNP2 protein; (iv) the pNP2-466 protein, whose amino acid sequence is constituted by the amino acid sequence comprised between moiety 1 and moiety 466 of the IBDN pNP2 protein; (v) the pNP2-476 protein, whose amino acid sequence is constituted by the amino acid sequence comprised between moiety 1 and moiety 476 of the IBDN pNP2 protein; (v)
- the IBDN pNP2 * protein present in the NLPs-pNP2 * provided by this invention has an amino acid sequence comprising between 441 and 501 amino acid residues, starting from residue number 1, of any PNP2 protein representative of any IBDN strain. , for example, of the IBDN pNP2 protein strain Soroa [ ⁇ CBI, accession number AAD30136].
- said IBDN pNP2 * protein present in the NLPs-pNP2 * provided by this invention is the pNP2-456 protein whose amino acid sequence is comprised between residue 1 and residue 456 of the IBDN pNP2 strain Soroa strain [ ⁇ CBI, access number AAD30136].
- the nucleotide sequence encoding said IBDN PNP2-456 protein extends from nucleotide 350 to nucleotide 1719 of the nucleotide sequence shown in SEQ. ID. ⁇ O: 1.
- the term "open reading phase corresponding to the IBDN pNP2 * protein” includes, in addition to the nucleotide sequences of said open reading phases, other open reading phases analogous to the same protein codes pNP2 * from IBDN.
- analog is intended to include any nucleotide sequence that can be isolated or constructed on the basis of the nucleotide sequence encoding pDN1 * of IBDN, for example, by introducing conservative nucleotide substitutions or non-conservative, including the insertion of one or more nucleotides, the addition of one or more nucleotides at any of the ends of the molecule or the deletion of one or more nucleotides at any end or within the sequence.
- a nucleotide sequence analogous to another nucleotide sequence is substantially homologous to said nucleotide sequence.
- substantially homologous means that the nucleotide sequences in question have a degree of identity, at the level of nucleotides, of at least 60%, preferably of at least 80%, more preferably of at least 90% and, even more preferably of at least 95%.
- IBDN NLPs-pNP2 * method for its production and applications
- the NLPs-pNP2 * provided by this invention can be obtained by expressing said IBDN pNP2 * protein, in appropriate host cells, in particular, yeasts, which contain the sequence of nucleotides encoding said IBDN pNP2 * protein in a gene construct.
- said appropriate host cells are yeasts transformed with a suitable expression system that includes a gene construct comprising the nucleotide sequence encoding said IBDN pNP2 * protein.
- the invention relates to a method for the production of NDNs-pNP2 * from IBDN, hereinafter method of the invention, comprising culturing a yeast containing the nucleotide sequence encoding an IBDN pNP2 * protein and expressing said IBDN pNP2 * protein, and, if desired, recovering said NLPs-pNP2 * of the invention.
- the process of the invention comprises the steps of: a) culturing yeast cells transformed with an expression system comprising the nucleotide sequence encoding an IBDN PNP2 * protein, wherein said pNP2 * protein is a protein whose amino acid sequence is constituted by the amino acid sequence comprised between the remainder 1 and the remainder "n" of the IBDN pNP2 protein, wherein "n” is an integer between 441 and 501, under conditions that allow the expression of said pNP2 * proteins and their assembly to form IBDN NLPs-pNP2 *; and b) if desired, isolate and, optionally, purify, said IBDN NLPs-pNP2 *.
- the process of the invention comprises the gene expression of an IBDN pNP2 * protein by the use of a vector that allows the expression of said protein in yeasts.
- the process of the invention comprises, as a previous step, the obtaining of a gene expression system, such as a system consisting of a plasmid containing a gene construct that codes for said IBDN pNP2 * protein, followed by transformation. of yeasts with said expression system, the expression of recombinant proteins, and, if desired, the isolation of NDNs-pNP2 * from IBDN formed by assembling said proteins
- PNP2 * of IBDN and, optionally, the purification of said NLPs-pNP2 *.
- Obtaining yeasts transformed with an expression system or vector that allows the expression of the IBDN pNP2 * protein can be carried out by a person skilled in the art based on what is described herein and the state of the art on this technology (epitope CFSP tagging vectors Instructions manual Stratagene www.stratagene.com; Sambrook
- the transformed yeasts are grown under conditions, known to those skilled in the art, which allow the expression of recombinant proteins (pNP2 *) and their assembly to form NDNs-pNP2 * of IBDN.
- pNP2 * recombinant proteins
- the expressed pNP2 * proteins are assembled and form the IBDN NLPs-pNP2 *, which can be isolated or removed from the medium, and, if desired, purified. Isolation and purification of said IBDN NLPs-pNP2 * of the invention can be carried out by conventional methods, for example, by fractionation in sucrose gradients.
- the expression system or vector used to transform yeasts comprises the nucleotide sequence encoding an IBDN pNP2 * protein operably linked to transcription and, optionally, translation control elements, and constitutes an additional aspect of this invention. Therefore, in another aspect, the invention provides an expression system or vector useful for transforming yeasts, comprising a nucleotide sequence encoding an IBDN pNP2 * protein, wherein said pNP2 * protein is a protein whose amino acid sequence it is constituted by the amino acid sequence comprised between the remainder 1 and the "n" moiety of the IBDN pNP2 protein, wherein "n” is an integer between 441 and 501, said nucleotide sequence encoding said pNP2 protein * of IBDN operatively linked to transcription and, optionally, translation control elements.
- said expression system comprises the nucleotide sequence comprising the open reading phase or coding region corresponding to a protein pNP2 * selected from proteins pNP2-441, pNP2-452, pNP2-456, pNP2-466, pNP2-476, pNP2-487, pNP2-494 and pNP2-501.
- the transcription and, optionally, translation control elements present in said expression system include promoters, which direct the transcription of the pNP2 * protein sequence (to which it is operably linked), and other sequences necessary or appropriate for transcription and its appropriate regulation in time and place, for example, start and end signals, cut sites, polyadenylation signal, origin of replication, transcriptional activators (enhancers), transcriptional silencers (silencers), etc., all useful in yeasts Virtually any appropriate expression system or vector can be used in the generation of said expression system.
- said vectors include plasmids, artificial yeast chromosomes (YACs), etc.
- said expression vector or system is a plasmid, such as a suitable plasmid for transforming yeasts based on a Yeast (Stratagene) pESC expression system, for example, the plasmid pESCURA / pNP2-456 (Example 1.1) which It contains a gene construct that codes for IBDN pNP2-456 protein and allows the production of NDNs-pNP2 * from IBDN in yeasts.
- the use of the gene expression system provided by this invention for the production and obtaining of NDNs-pNP2 * from IBDN constitutes a further aspect of this invention.
- the invention provides a host cell, such as a yeast, that contains a nucleotide sequence encoding said IBDN PNP2 * protein.
- said host cell is a yeast transformed with an expression system provided by this invention comprising a gene construct comprising the nucleotide sequence encoding said IBDN pNP2 * protein.
- Virtually any yeast can be used for the implementation of the process of the invention; however, in a particular embodiment, said yeast is a yeast of the genus Saccharomyces, by for example, S. cerevisae, S. pombe, etc., a yeast of the genus Pichia, for example, P. pastoris, etc.
- IBDN NLPs-pNP2 * can be used as vectors or carriers of products of interest, such as molecules with biological activity, for example, drugs, polypeptides, proteins, nucleic acids, etc., so they can be used for therapeutic purposes. , diagnostic or research.
- said molecules of biological interest include polypeptides of interest, such as antigens or inducers of immune responses in animals or humans to which they are delivered, or include nucleic acid sequences, useful in gene therapy, intended to be introduced. inside the appropriate cells.
- IBDN NLPs-pNP2 * can be used to immunize animals, in particular, birds, per se or as vectors or carriers of molecules with biological activity, for example, polypeptides, proteins, nucleic acids, drugs, etc., whereby They can be used for therapeutic or diagnostic purposes.
- said molecules with biological activity include antigens or inducers of immune responses in animals or humans to which they are supplied, or drugs that are released at their specific site of action, or nucleic acid sequences, all useful. in gene therapy and intended to be introduced into the appropriate cells. Therefore, in another aspect, the invention relates to the use of said
- IBDN NLPs-pNP2 * in the development of medications such as vaccines, gene therapy vectors (delivery systems), etc.
- said medicament is a vaccine intended to confer protection to animals, in particular, birds, against IBDN.
- said medicament is a vector for gene therapy.
- the invention provides a vaccine comprising a therapeutically effective amount of NDNs-pNP2 * from IBDN, together with, optionally, one or more pharmaceutically acceptable adjuvants and / or vehicles. This vaccine is useful for protecting animals, particularly birds, against IBDN.
- the vaccine provided by this invention is a vaccine useful for protecting chickens from infection caused by IBDN.
- the term "therapeutically effective amount” refers to the amount of NLPs-pNP2 * of the invention calculated to produce the desired effect and, in general, will be determined, among other causes, by the proper characteristics. of the NLPs-pNP2 * of the invention and the immunization effect to be achieved.
- the pharmaceutically acceptable adjuvants and vehicles that can be used in said vaccines are the adjuvants and vehicles known to those skilled in the art and commonly used in vaccine production.
- said vaccine is prepared in the form of an aqueous solution or suspension, in a pharmaceutically acceptable diluent, such as saline, phosphate buffered saline (PBS), or any other pharmaceutically acceptable diluent.
- a pharmaceutically acceptable diluent such as saline, phosphate buffered saline (PBS), or any other pharmaceutically acceptable diluent.
- the vaccine provided by this invention may be administered by any appropriate route of administration that results in a protective immune response against the heterologous sequence or epitope used, for which said vaccine will be formulated in the pharmaceutical form appropriate to the route of administration chosen. .
- the administration of the vaccine provided by this invention is carried out parenterally, for example, intraperitoneally, subcutaneously, etc.
- Example 1 illustrates the obtaining of NLPs-pNP2- 456 from IBDN
- Example 2 demonstrates the antigenic ability of said NLPs-pNP2-456 of IBDN in chickens.
- EXAMPLE 1 Obtaining VLPs-pVP2 * by expressing various regions of the pVP2 protein in yeasts 1.1 Obtaining NLPs-pNP2-465 by expressing the region 1-456 of the pNP2 protein in yeasts In order to study the possibility to obtain IBDN NLPs formed by self-assembly of the pNP2-456 protein, whose amino acid sequence is constituted by the amino acid sequence comprised between the remainder 1 and the remainder 456 of the protein
- IBDN PNP2 called NLPs-pNP2-456
- yeast cultures Sacharomyces cerevisiae
- the vector pESCURAinv / pNP2-456 was generated.
- the first step in the construction of the vector was performed by cloning the coding region of the pNP2-456 protein (residues 1-456 of the pNP2 of IBDN) into the pESCURAinv vector.
- the plasmid pESCURAinv was generated by digesting the vector pRS426 (Stratagene) with the enzyme PvuII and religating the digestion mixture.
- the resulting vector, pESCURAinv contains the region of multiple cloning in an inverted position with respect to that of the parental vector pRS426.
- the D ⁇ A fragment corresponding to the pNP2- 456 protein was obtained by PCR with the oligonucleotides identified as Oligo I (SEQ ID ⁇ O: 2) and Oligo II (SEQ ID ⁇ O: 3) using the plasmid pNOTE.2 / Poly as a template ( Fernández-Arias A et al. 1998. Expression of ORF Al of infectious bursal disease virus infectious bursal disease virus results in the formation of virus-like particles. Journal of General Virology 79: 1047-1054).
- Plasmid pESCURAinv / pNP2-456 was used to transform a S. cerevisiae haploid strain 499 yeast culture according to a previously described protocol (Gietz & Woods. 2002. Transformation of yeast by the Liac / SS carrier D ⁇ A / PEG method. Methods in Enzymology 350: 87-96).
- Yeasts transformed with the plasmid were selected by growth in SC medium plates (CSM + Y ⁇ B, 2% glucose and agar agar) supplemented with the amino acids tryptophan, leucine and histidine and lacking uracil (-Ura). After an incubation of 48 h at 30 ° C, a colony was selected which was used for the subsequent analysis of protein expression and NLPs formation.
- SC medium plates CSM + Y ⁇ B, 2% glucose and agar agar
- a colony was selected which was used for the subsequent analysis of protein expression and NLPs formation.
- the analysis of pNP2-456 protein expression and NLPs formation was performed following a previously described protocol for the characterization of IBDN NLPs in other expression systems (Fernández-Arias A et al. 1998. Expression of ORF Al of infectious bursal disease virus results in the formation of virus-like particles.
- NP1 the putative R ⁇ A-dependent R ⁇ A polymerase of infectious bursal disease virus, forms complexes with the capsid protein NP3, leading to efficient encapsidation into virus-like particles. Journal of Virology 73: 6973-698).
- the selected colony was grown in liquid medium CSM (-Ura) + Y ⁇ B supplemented with 2% raffinose. The culture was incubated at 30 ° C for 24 h.
- This culture was used to inoculate, at an optical density (OD) of 0.2, a 200 ml flask of CSM medium (-Ura) + YNB supplemented with the 2% galactose inducer.
- the culture was maintained at 30 ° C for 18 hours (up to an OD between 1.0 and 2.0).
- the yeasts were centrifuged at 3,000 rpm, for 5 minutes at 4 ° C, washed with distilled water 1 time, and the pellet was resuspended in lysis buffer (TEN: 10 mM Tris, pH
- NP1 the putative R ⁇ A-dependent R ⁇ A polymerase of infectious bursal disease virus, forms complexes with the capsid protein NP3, leading to efficient encapsidation into virus-like particles. Journal of Virology 73: 6973-6983).
- SDS-PAGE sodium dodecyl sulfate
- EXAMPLE 2 Characterization of the immunogenicity of IBDV VLPs-pVP2-456 In order to determine the immunogenicity of NLPs-pNP2-456 (Example 1.1), a 1-day-old chicken immunization test was performed. A group of 7 SPF animals (free of specific pathogens) was immunized intramuscularly with a single dose of 200 ⁇ l containing 10 ⁇ g of NLPs-pNP2-456 / animal diluted in PBS. A similar group was injected with PBS. Weekly serum extractions were performed from each of the animals of both groups. The sera of each group and date were mixed to obtain a homogeneous serum (pool) represented by equivalent volumes of each individual in the group. The sera were analyzed by ELISA.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05743930A EP1752468A1 (en) | 2004-04-30 | 2005-04-27 | Method for the production of empty viral capsids in yeasts, said capsids comprising proteins derived from pvp2 of the virus that causes infectious bursal disease (ibdv) |
US10/576,778 US20070212375A1 (en) | 2004-04-30 | 2005-04-27 | Process For Producing In Yeast Empty Viral Capsids Consisting Of Proteins Derived From Pvp2 Of The Infectious Bursal Disease Virus (Ibdv) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200401044 | 2004-04-30 | ||
ES200401044A ES2242542B1 (es) | 2004-04-30 | 2004-04-30 | Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv). |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005105834A1 true WO2005105834A1 (es) | 2005-11-10 |
Family
ID=35241624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2005/070052 WO2005105834A1 (es) | 2004-04-30 | 2005-04-27 | Procedimiento para la producción en levaduras de cápsidas virales vacías compuestas por proteínas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv) |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070212375A1 (es) |
EP (1) | EP1752468A1 (es) |
ES (1) | ES2242542B1 (es) |
WO (1) | WO2005105834A1 (es) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7476387B2 (en) | 2005-07-15 | 2009-01-13 | Chimera Pharma S.L.U. | Chimeric empty viral-like particles derived from the infectious bursal disease virus (IBDV), process for their production and applications |
WO2011054995A2 (es) | 2009-11-06 | 2011-05-12 | Chimera Pharma, S. L. U. | VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE |
WO2011054996A2 (es) | 2009-11-06 | 2011-05-12 | Chimera Pharma, S. L. U. | Vacunas para el tratamiento de neoplasias a partir de capsides virales de birnavirus conteniendo antigenos del virus del papiloma humano |
EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
CN111662364A (zh) * | 2020-06-28 | 2020-09-15 | 山西农业大学 | 传染性法氏囊病病毒vp2蛋白及其编码基因与应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8450056B2 (en) * | 2008-05-02 | 2013-05-28 | University Of Rochester | Arrayed imaging reflectometry (AIR) sensor chip comprising virus-like particles suitable for the detection of antiviral immune responses |
US8486619B2 (en) * | 2008-05-02 | 2013-07-16 | University Of Rochester | Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses |
CN102145166B (zh) * | 2011-04-21 | 2013-05-22 | 江苏省农业科学院 | 重组禽流感M2e的鸡传染性法氏囊VP2亚单位疫苗、其构建方法及其应用 |
DE102011121069A1 (de) | 2011-12-13 | 2013-06-13 | Martin-Luther-Universität Halle-Wittenberg | Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene |
SG11202010533WA (en) * | 2018-04-30 | 2020-11-27 | Amicus Therapeutics Inc | Gene therapy constructs and methods of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614409A (en) * | 1989-05-30 | 1997-03-25 | Commonwealth Scientific And Industrial Research Organisation | Production of IBDV VP2 in highly immunogenic form |
-
2004
- 2004-04-30 ES ES200401044A patent/ES2242542B1/es not_active Expired - Fee Related
-
2005
- 2005-04-27 US US10/576,778 patent/US20070212375A1/en not_active Abandoned
- 2005-04-27 EP EP05743930A patent/EP1752468A1/en not_active Withdrawn
- 2005-04-27 WO PCT/ES2005/070052 patent/WO2005105834A1/es active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614409A (en) * | 1989-05-30 | 1997-03-25 | Commonwealth Scientific And Industrial Research Organisation | Production of IBDV VP2 in highly immunogenic form |
Non-Patent Citations (4)
Title |
---|
CASTON J.R. ET AL: "C terminus of infectious bursal disease virus major capsid protein VP2 is involved in definition of the T number for capsid assembly.", JOURNAL OF VIROLOGY., vol. 75, no. 22, November 2001 (2001-11-01), pages 10815 - 10828, XP008074347 * |
LEJAL N. ET AL: "Role of Ser-652 and Lys-692 in the protease activity of infectious bursal disease virus VP4 and identification of its substrate cleavage sites.", JOURNAL OF GENERAL VIROLOGY., vol. 81, 2000, pages 938 - 992, XP008074341 * |
MARTINEZ-TORRECUADRADA J.L. ET AL: "Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines.", VACCINE., vol. 21, no. 23, July 2003 (2003-07-01), pages 3342 - 3350, XP004429746 * |
PITCOVSKI J. ET AL: "Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens.", VACCINE., vol. 21, no. 32, December 2003 (2003-12-01), pages 4736 - 4743, XP004469693 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7476387B2 (en) | 2005-07-15 | 2009-01-13 | Chimera Pharma S.L.U. | Chimeric empty viral-like particles derived from the infectious bursal disease virus (IBDV), process for their production and applications |
WO2011054995A2 (es) | 2009-11-06 | 2011-05-12 | Chimera Pharma, S. L. U. | VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE |
WO2011054996A2 (es) | 2009-11-06 | 2011-05-12 | Chimera Pharma, S. L. U. | Vacunas para el tratamiento de neoplasias a partir de capsides virales de birnavirus conteniendo antigenos del virus del papiloma humano |
EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
WO2012131139A1 (es) | 2011-03-29 | 2012-10-04 | Neo Virnatech, S.L. | Composiciones de vacuna para enfermedades transmitidas por birnavirus |
CN111662364A (zh) * | 2020-06-28 | 2020-09-15 | 山西农业大学 | 传染性法氏囊病病毒vp2蛋白及其编码基因与应用 |
Also Published As
Publication number | Publication date |
---|---|
US20070212375A1 (en) | 2007-09-13 |
ES2242542A1 (es) | 2005-11-01 |
ES2242542B1 (es) | 2006-12-16 |
EP1752468A1 (en) | 2007-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005105834A1 (es) | Procedimiento para la producción en levaduras de cápsidas virales vacías compuestas por proteínas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv) | |
ES2371833T3 (es) | Partículas quiméricas vacías similares a virus derivadas del virus de la enfermedad de la bursitis infecciosa (ibdv), proceso para su producción y aplicaciones. | |
ES2514316T3 (es) | Partículas similares a virus (VLPs) de Norovirus y Sapovirus | |
EP1706486B1 (en) | Chimeric empty capsids of the infectious bursal disease virus (ibdv), obtainment process and applications | |
KR101608121B1 (ko) | 노다바이러스의 바이러스 유사입자의 생산방법, 이를 발현하는 효모 세포주 및 이를 포함하는 백신 조성물 | |
ES2294679T3 (es) | Capsidas vacias (vlps(vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. | |
CN113862284A (zh) | 一种编码重组禽流感病毒ha蛋白的基因、病毒样颗粒、疫苗及制备与应用 | |
CN108431214B (zh) | 人轮状病毒g9p[6]毒株和作为疫苗的用途 | |
WO2023207717A1 (zh) | H5n8禽流感广谱性疫苗的开发及其应用 | |
CN106905434A (zh) | 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用 | |
US6187319B1 (en) | Cross-protective rotavirus vaccine | |
KR102365464B1 (ko) | 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법 | |
CN116785424B (zh) | 一种mRNA多价流感疫苗及其制备方法 | |
RU2709328C1 (ru) | Антиген для рекомбинантной вакцины против вируса краснухи | |
WO2022195900A1 (ja) | 組換え麻疹ウイルス | |
WO2004087900A1 (es) | Partículas virales vacías completas del virus inductor de la bursitis infecciosa (ibdv), procedimiento para su producción y aplicaciones | |
BR102018011834A2 (pt) | polipeptídeo flaviviral com finalidade vacinal e diagnostica produzido em planta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005743930 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005743930 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10576778 Country of ref document: US Ref document number: 2007212375 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10576778 Country of ref document: US |